PURPOSE: Sorafenib, an oral multitargeted tyrosine kinase inhibitor, is highly bound to plasma proteins (>99.5%). Little is known about the influence of variations in sorafenib protein binding on its disposition. The aims of this study were to characterize in vitro sorafenib binding properties to albumin using the quenching fluorescence method and investigate the influence of albuminemia and bilirubinemia on sorafenib disposition in 54 adult cancer patients. RESULTS: In vitro estimate of sorafenib dissociation constant (Kd) for albumin was 0.22 μM [CI95 0.20-0.23]. In physiological conditions, sorafenib unbound fraction would increase 1.7-fold as albuminemia decreased from 45 g/L (680 μM) to 30 g/L (453 μM). In presence of bilirubin, apparent Kd of sorafenib was ~1.5-fold greater for bilirubin/albumin molar ratio of 1:4. In clinical settings, median sorafenib clearance (CL) was 1.42 L/h (0.75-2.13 L/h). In univariate analysis, sex, body mass index, and albuminemia were associated with CL (p = 0.04, 0.048, and 0.008, respectively). In multivariate analysis, albuminemia (p = 0.0036) was the single parameter independently associated with CL. CONCLUSION: These findings highlight the major influence of albuminemia on sorafenib clearance and its disposition in cancer patients.
PURPOSE:Sorafenib, an oral multitargeted tyrosine kinase inhibitor, is highly bound to plasma proteins (>99.5%). Little is known about the influence of variations in sorafenib protein binding on its disposition. The aims of this study were to characterize in vitro sorafenib binding properties to albumin using the quenching fluorescence method and investigate the influence of albuminemia and bilirubinemia on sorafenib disposition in 54 adult cancerpatients. RESULTS: In vitro estimate of sorafenib dissociation constant (Kd) for albumin was 0.22 μM [CI95 0.20-0.23]. In physiological conditions, sorafenib unbound fraction would increase 1.7-fold as albuminemia decreased from 45 g/L (680 μM) to 30 g/L (453 μM). In presence of bilirubin, apparent Kd of sorafenib was ~1.5-fold greater for bilirubin/albumin molar ratio of 1:4. In clinical settings, median sorafenib clearance (CL) was 1.42 L/h (0.75-2.13 L/h). In univariate analysis, sex, body mass index, and albuminemia were associated with CL (p = 0.04, 0.048, and 0.008, respectively). In multivariate analysis, albuminemia (p = 0.0036) was the single parameter independently associated with CL. CONCLUSION: These findings highlight the major influence of albuminemia on sorafenib clearance and its disposition in cancerpatients.
Authors: Dirk Strumberg; Jeffrey W Clark; Ahmad Awada; Malcolm J Moore; Heike Richly; Alain Hendlisz; Hal W Hirte; Joseph P Eder; Heinz-Josef Lenz; Brian Schwartz Journal: Oncologist Date: 2007-04
Authors: Brenda C M de Winter; Teun van Gelder; Ferdi Sombogaard; Leslie M Shaw; Reinier M van Hest; Ron A A Mathot Journal: J Pharmacokinet Pharmacodyn Date: 2009-11-11 Impact factor: 2.745
Authors: Antonius A Miller; Daryl J Murry; Kouros Owzar; Donna R Hollis; Erin B Kennedy; Ghassan Abou-Alfa; Apurva Desai; Jimmy Hwang; Miguel A Villalona-Calero; E Claire Dees; Lionel D Lewis; Marwan G Fakih; Martin J Edelman; Fred Millard; Richard C Frank; Raymond J Hohl; Mark J Ratain Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312
Authors: Maria Cristina Villarroel; Keith W Pratz; Linping Xu; John J Wright; B Douglas Smith; Michelle A Rudek Journal: Invest New Drugs Date: 2011-11-17 Impact factor: 3.850
Authors: N Pécuchet; C Lebbe; O Mir; B Billemont; B Blanchet; N Franck; M Viguier; R Coriat; M Tod; M-F Avril; F Goldwasser Journal: Br J Cancer Date: 2012-07-05 Impact factor: 7.640
Authors: S Karovic; Y Wen; T G Karrison; G L Bakris; M R Levine; L K House; K Wu; V Thomeas; M A Rudek; J J Wright; E E W Cohen; G F Fleming; M J Ratain; M L Maitland Journal: Clin Pharmacol Ther Date: 2014-03-17 Impact factor: 6.875